Trials / Withdrawn
WithdrawnNCT02521077
Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Midwestern Regional Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ascorbic Acid | 500 g ascorbic acid dissolved in 500 ml sterile water. |
| OTHER | Normal Saline | Saline 0.9% |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2015-08-13
- Last updated
- 2017-06-27
Source: ClinicalTrials.gov record NCT02521077. Inclusion in this directory is not an endorsement.